|
94 Companies |
|
165 Products |
|
165 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
1453 News |
|
| «12...56789101112131415...2930» |
- Enrollment closed, Trial primary completion date: VEDROP: Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention (clinicaltrials.gov) - Dec 24, 2014
P3, N=14, Active, not recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Aug 2015
- Enrollment open: SomaghLipid: The Effects of Rhus Coriaria L. on Serum Lipid Levels of Patients With Hyperlipidemia (clinicaltrials.gov) - Dec 20, 2014
P0, N=80, Recruiting, Sponsor: Shiraz University of Medical Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Aug 2015 Not yet recruiting --> Recruiting
- Biomarker, Trial primary completion date: Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=200, Recruiting, Sponsor: George Washington University
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Jun 2015
- |||||| Praluent (alirocumab) / Sanofi, Regeneron
Enrollment open, Trial initiation date: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan (clinicaltrials.gov) - Dec 19, 2014
P3, N=184, Recruiting, Sponsor: Sanofi
Trial primary completion date: Jul 2014 --> Jun 2015 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Oct 2014
- Trial completion, Trial primary completion date: Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=12, Completed, Sponsor: Universita di Verona
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Oct 2014 Recruiting --> Completed | Trial primary completion date: Sep 2013 --> Dec 2013
- ||||| Repatha (evolocumab) / Amgen, Astellas
Enrollment closed, Adverse events: GAUSS-3: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (clinicaltrials.gov) - Dec 17, 2014
P3, N=519, Active, not recruiting, Sponsor: Amgen
Recruiting --> Completed | Trial primary completion date: Sep 2013 --> Dec 2013 Recruiting --> Active, not recruiting
- | Trial completion, Trial primary completion date, HEOR: CROSSROADS: Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults (clinicaltrials.gov) - Dec 17, 2014
P3, N=167, Completed, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2014 --> Aug 2014
- ||| Leqvio (inclisiran) / Alnylam, Novartis
Enrollment open: A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C) (clinicaltrials.gov) - Dec 14, 2014
P1, N=76, Recruiting, Sponsor: Alnylam Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jan 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- PF-06427878 / Pfizer
Enrollment change: A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects (clinicaltrials.gov) - Dec 13, 2014
P1, N=16, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=24 --> 16
- ||| Trial completion: Lentils as a Functional Food to Improve Glucose and Decrease Cardiovascular Risk (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=102, Completed, Sponsor: University of Manitoba
N=24 --> 16 Recruiting --> Completed
- ||| Leqvio (inclisiran) / Alnylam, Novartis
New P1 trial: A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C) (clinicaltrials.gov) - Dec 11, 2014
P1, N=76, Recruiting, Sponsor: Alnylam Pharmaceuticals
- Preclinical: Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=6, Recruiting, Sponsor: Tufts University
- | Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion, Trial primary completion date: The Effect of Type 2 Diabetes and Dietary Regulation on VLDL1-and VLDL2-triglyceride Metabolism (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=30, Completed, Sponsor: University of Aarhus
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Dec 2014
- Trial primary completion date: IL-7norm: Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=55, Recruiting, Sponsor: University Hospital, Lille
Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Dec 2014 Trial primary completion date: Dec 2013 --> Dec 2015
- Enrollment closed, Trial primary completion date, Adherence: The Effect of Synching Prescription Refills on Adherence (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=976, Active, not recruiting, Sponsor: University of Pennsylvania
Trial primary completion date: Dec 2013 --> Dec 2015 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Jan 2015
- Trial completion, Trial primary completion date: Risk Assessment of Long-Haul Truck Drivers (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=294, Completed, Sponsor: Wake Forest School of Medicine
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Jan 2015 Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Mar 2010
- ||| Trial initiation date: A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004) (clinicaltrials.gov) - Dec 9, 2014
P2, N=191, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Mar 2010 Initiation date: Feb 2009 --> Jun 2008
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
New P3 trial: Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab (clinicaltrials.gov) - Dec 7, 2014
P3, N=642, Enrolling by invitation, Sponsor: Amgen
- Enrollment closed: Dietary Carbohydrate Type and Cardiovascular Disease (CVD) Risk Indicators (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=10, Active, not recruiting, Sponsor: Tufts University
Initiation date: Feb 2009 --> Jun 2008 Recruiting --> Active, not recruiting
- | Trial completion, Trial primary completion date: Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=40, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2013
- Trial primary completion date: Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=20, Recruiting, Sponsor: Tufts University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2013 Trial primary completion date: Dec 2014 --> Jul 2015
- || Trial primary completion date: Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=60, Active, not recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Dec 2013 --> Oct 2014
- Phase classification: Soybean Based Diets and CVD Risk Factors (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=30, Completed, Sponsor: Tufts University
Trial primary completion date: Dec 2013 --> Oct 2014 Phase classification: P4 --> P=N/A
- ezetimibe/simvastatin / Generic mfg.
Clinical: Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=40, Completed, Sponsor: Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
- |||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo
Trial completion: Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients (clinicaltrials.gov) - Dec 6, 2014
P2, N=349, Completed, Sponsor: Esperion Therapeutics
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed
- Trial completion, Gene therapy: Gene Therapy for Tay-Sachs Disease (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=4, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment closed, Trial primary completion date: Effect of Different Types of Carbohydrates Consumed After Exercise on Blood Fat Levels (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=25, Active, not recruiting, Sponsor: University of Saskatchewan
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Feb 2015
- pravastatin / Generic mfg.
Trial primary completion date: OxLDL: Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome (clinicaltrials.gov) - Dec 5, 2014
P1, N=10, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Feb 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- ||||| New P4 trial: Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia (clinicaltrials.gov) - Dec 5, 2014
P4, N=68, Completed, Sponsor: Kuhnil Pharmaceutical Co., Ltd.
- Clinical: The CREATE Wellness Study (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=588, Not yet recruiting, Sponsor: Kaiser Permanente
- |||||| evacetrapib (LY2484595) / Eli Lilly
Enrollment open: A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia (clinicaltrials.gov) - Nov 28, 2014
P3, N=52, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- ||||||| anacetrapib (MK-0859) / Merck (MSD)
Trial completion: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021) (clinicaltrials.gov) - Nov 25, 2014
P3, N=459, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- PF-06427878 / Pfizer
Enrollment closed: A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects (clinicaltrials.gov) - Nov 24, 2014
P1, N=24, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: ECCA: Effect of Cheese on Cardiovascular Risk (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=19, Completed, Sponsor: University of Copenhagen
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change: Intravenous Fat Emulsions and Premature Infants (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=19, Terminated, Sponsor: OSF Healthcare System
Recruiting --> Completed N=11 --> 19
- Clinical: SomaghLipid: The Effects of Rhus Coriaria L. on Serum Lipid Levels of Patients With Hyperlipidemia (clinicaltrials.gov) - Nov 20, 2014
P0, N=80, Not yet recruiting, Sponsor: Shiraz University of Medical Sciences
- Trial completion: Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=100, Completed, Sponsor: Shaare Zedek Medical Center
N=11 --> 19 Not yet recruiting --> Completed
- Trial primary completion date, Adherence: Is a Smartphone Application Effective as an Oral Medication Adherence Aid (clinicaltrials.gov) - Nov 14, 2014
P0, N=228, Recruiting, Sponsor: University of Arkansas
Not yet recruiting --> Completed Trial primary completion date: Oct 2014 --> Oct 2015
- |||||||||| Praluent (alirocumab) / Sanofi, Regeneron
New P3 trial: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan (clinicaltrials.gov) - Nov 13, 2014
P3, N=184, Not yet recruiting, Sponsor: Sanofi
- ||| Clinical: The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=214, Recruiting, Sponsor: Unilever R&D
- Enrollment change, Trial termination, Trial primary completion date: Enzyme Replacement Therapy in Fabry Disease (clinicaltrials.gov) - Nov 11, 2014
P=N/A, N=2, Terminated, Sponsor: Mario Negri Institute for Pharmacological Research
Trial primary completion date: Oct 2014 --> Oct 2015 N=20 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Oct 2008; Difficulties in the patient's enrolment
- |||||| bococizumab (RN316) / Pfizer
Enrollment open: SPIRE-LL: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Nov 11, 2014
P3, N=690, Recruiting, Sponsor: Pfizer
N=20 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Oct 2008; Difficulties in the patient's enrolment Not yet recruiting --> Recruiting
- | rosuvastatin / Generic mfg.
Enrollment open: HYDRA: A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Nov 11, 2014
P3, N=25, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Clinical: Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Nov 10, 2014
P=N/A, N=9, Active, not recruiting, Sponsor: Laval University
- ||| bococizumab (RN316) / Pfizer
Enrollment closed: Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects (clinicaltrials.gov) - Nov 5, 2014
P2, N=216, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- fenofibrate / Generic mfg.
Trial completion: Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate (clinicaltrials.gov) - Nov 4, 2014
P4, N=120, Completed, Sponsor: Gachon University Gil Medical Center
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial completion: Vascular and Metabolic Effects of Omega-3 Fatty Acids (clinicaltrials.gov) - Nov 4, 2014
P4, N=176, Completed, Sponsor: Gachon University Gil Medical Center
Recruiting --> Completed Recruiting --> Completed
- Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Enrollment open, Trial primary completion date: ECLIPSEIV: An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova (clinicaltrials.gov) - Nov 4, 2014
P1, N=24, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> May 2015
- simvastatin / Generic mfg., ezetimibe/simvastatin / Generic mfg.
Trial completion, Enrollment change: Vascular and Metabolic Effects of Vytorin vs Simvastatin (clinicaltrials.gov) - Nov 4, 2014
P4, N=204, Completed, Sponsor: Gachon University Gil Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> May 2015 Recruiting --> Completed | N=120 --> 204
- ezetimibe/simvastatin / Generic mfg.
Trial completion, Enrollment change: Vascular and Metabolic Effects of Vytorin (clinicaltrials.gov) - Nov 4, 2014
P4, N=204, Completed, Sponsor: Gachon University Gil Medical Center
Recruiting --> Completed | N=120 --> 204 Recruiting --> Completed | N=120 --> 204